Although an increase in nitric oxide (NO) in muscle is reported to improve the outcome of deflazacort treatment for mdx mouse muscular dystrophy, the genetic homologue of Duchenne muscular dystrophy (DMD), the impact such treatment on the functional outcomes of the disease, including fiber susceptibility to exercise-induced injury, is not established. Experiments were designed to test whether treatment with deflazacort and L-arginine (a substrate for NO synthase, NOS) would change the extent of fiber injury induced by 24 h of voluntary exercise. The impact of exercise-related injury to induce a secondary regenerative response by muscle was also examined as corroborating evidence of muscle damage. Dystrophic mdx mice were treated for 3 wk with placebo, deflazacort, or deflazacort plus either L-arginine or N G -nitro-L-arginine methyl ester (a NOS inhibitor). Deflazacort, especially combined with L-arginine, spared quadriceps muscle from injury-induced regeneration (myf5 expression) compared with placebo treatment, despite an increase in membrane permeability immediately after exercise (assessed by Evans blue dye infiltration). Deflazacort alone prevented the typical progressive loss of function (measured as voluntary distance run over 24 h) that was observed 3 months later in placebotreated mice. Therefore, combined deflazacort plus L-arginine treatment spared mdx dystrophic limb muscle from exercise-induced damage and the need for regeneration and induced a persistent functional improvement in distance run. Results suggest a potential new treatment option for improving the quality of life for boys with DMD.
examining potential benefits of a range of genetic, cell, and drug-based therapies that may improve disease outcome, including the possibility of improving muscle regeneration that could partly offset progression of the disease. Overexpression of utrophin, a protein proposed to substitute for dystrophin at the sarcolemma, and transgenic expression of mini-dystrophin both markedly reduce mdx mouse dystrophy (1, (10) (11) (12) (13) (14) (15) (16) (17) . Furthermore, the effectiveness of the model extends to the level of the muscle fiber-satellite cell unit, which demonstrates central nucleation and alterations in myogenic differentiation by satellite cells that are typical of mdx mouse muscular dystrophy (18) (19) (20) (21) (22) (23) .
The current "gold standard" drug therapy in DMD uses glucocorticoids such as prednisone and its analog, deflazacort (24, 25) . In DMD and mdx dystrophy, these steroids reduce the secondary inflammation that extends muscle fiber necrosis outside the region of primary damage caused by membrane breaks such as induced by exercise or eccentric muscle contraction (26, 27) . In addition to the major anti-inflammatory effect of glucocorticoids in dystrophic muscle (28) , deflazacort also up-regulates calcineurin/NF-AT pathway activity, which negates the musclespecific activation of JNK1, and results in damage to dystrophic fibers (29, 30). In mdx mice treated for 3-4 wk after the onset of dystrophic muscle damage, the benefits of deflazacort and prednisone treatment are therefore well established (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . Deflazacort treatment also advances muscle regeneration through increased proliferation of muscle precursor cells that are identified by expression of the muscle regulatory gene myf5, increases precursor cell fusion into regenerating fibers, and promotes the growth of undamaged fibers and hypertrophy of new fibers formed during treatment (32). Steroid treatment of mdx mice reduces disease severity, as measured by a lower central nucleation index, a marker of cumulative muscle regeneration, and by functional improvement including greater strength of forearm grip and whole body pull (31, 36).
Satellite cells are muscle precursors that are typically quiescent in normal muscle and are activated by a stimulus to initiate muscle regeneration or growth. The process of activation is mediated by nitric oxide (NO) (37), a molecule produced by the enzymatic activity of NO synthase (NOS) on L-arginine and ensuing signaling via hepatocyte growth factor interaction with c-met receptor on satellite cells (38) (39) (40) (41) (42) . Although the muscle isoform of neuronal NOS, nNOSµ, is normally localized to the DGC via α1-syntrophin, dystrophin-deficiency downregulates expression of nNOSµ mRNA and protein. Loss of nNOSµ from the DGC in mdx dystrophy is thought to underlie changes in the time course of satellite cell activation in response to muscle injury (37, 43, 44) , and restoration of nNOS to the sarcolemma is a useful marker of dystrophin restoration in dystrophic muscle (45) . Interestingly, exposure of muscle cell cultures to L-arginine and treatment of mdx mice in vivo with L-arginine and/or deflazacort result in an increase in utrophin protein expression (17, 30, (46) (47) (48) . As well, overexpression of nNOS in mdx dystrophic mice alleviates the progression of dystrophy in skeletal and cardiac muscle (49) (50) (51) (52) . The benefits of deflazacort on mdx mouse muscle repair are also increased by L-arginine, as demonstrated by increased myf5 and nNOSµ expression in muscle regenerating from crush injury and some sparing from dystrophy in diaphragm muscle (33). The impact of the combined treatment on the functional outcome of dystrophy, including on the hallmark sign of fiber susceptibility to voluntary exercise, is not known.
Experiments were designed to test the hypothesis that combined treatment with deflazacort and L-arginine (D+LA) would mitigate the hallmark of dystrophic muscle fibers, susceptibility to injury induced by a physiological level of activity resulting from 24 h of voluntary exercise.
Treatment effects were anticipated to involve decreases in muscle fiber permeability to EBD, an increase in muscle precursor cell proliferation, and some reduction in the progressive loss of function during mdx mouse muscular dystrophy.
MATERIALS AND METHODS

Animals and treatment
Animals were housed according to regulations set by the Canadian Council on Animal Care and approved by the University of Manitoba (protocol #R99-003). Experiments were designed to study functional, cell, and tissue effects of voluntary exercise in mdx mice receiving different treatments for 3 wk and examine the persistence of such effects 3 months later.
Dystrophic mdx mice (C57Bl/10ScSn, JAX laboratories) at 4 wk old were randomly assigned to groups (n=8-10 each) and treated (double-blind) with one of a placebo (PL, methylcellulose, 0.5% in saline); deflazacort (D, 1.2 mg/kg/day in methylcellulose subcutaneously by Hamilton syringe); deflazacort plus L-arginine in drinking water (D+LA, 0.375%); or deflazacort plus the NOS inhibitor N G -nitro-L-arginine methyl ester (L-NAME) in drinking water (D+LN, 0.0125%) for a total of 3 wk, as reported (33, 37). Three different experimental protocols that employed this treatment regimen are depicted in Fig. 1 and briefly included protocol 1: acute, after exercise; protocol 2: short-term after exercise-induced regeneration; and protocol 3: long-term after 3 months without treatment, and included the end points described as follows, for various measures below.
Voluntary exercise
A steel rodent wheel (12.7 cm diameter) was lined with fine fiberglass netting to provide mice with a continuous running surface. Small (1 cm 2 ) magnets were attached on opposite sides of the wheel circumference, so they would trigger (twice per rotation) a magnetic switch (Guard   TM   ) connected to a counter-recorder (Omron TM Type H7EC-BLM). Animals were placed in cages with a running wheel at noon, allowed voluntary access to the wheel for the next 24 h (including overnight, when they were most active), and then killed at noon the following day or returned to cages for 4 days (protocols 1 and 2, respectively, as described below). Total distance run in 24 h was calculated using simple mathematics. Distance run was normalized to body weight to account for differences in wheel loading that could affect running capacity among different-sized mice within each group (53) .
A pilot study was used to determine the induction of fiber damage by 24 h of voluntary exercise as follows. Mice were acclimatized in groups of 3 for 60 min to an exercise wheel in a large cage. All mice voluntarily entered the wheel and ran. After familiarization, mice were placed in separate cages for 24 h of voluntary exercise, with videotaping overnight to confirm activity and safety on the running wheel.
Experimental design
Three experimental protocols and end points are reported (Fig. 1 ). Mice were euthanized by cervical dislocation under anesthesia as follows. Protocol 1 ended immediately after the exercise period (17 days of treatment) to allow studies of the effect of voluntary exercise on muscle fiber damage using the Evans blue dye (EBD) method. In protocol 2, 4 days after the end of exercise ) to label DNA synthesis, an index of satellite cell activation after voluntary exercise. This protocol was used to examine the extent of muscle cell proliferation and regeneration 4 days after exercise-induced injury. For protocol 3, a third set of animal groups was treated for 21 days. Half the mice in each treatment group were exercised and killed, as in protocol 1; the other half of each group was maintained for a further 3 months to examine the longer term outcome of treatment on exercise-induced fiber damage. After 3 months without treatment (19 wk-of-age), animals in this long-term study were exposed to 24 h of voluntary exercise and then killed under anesthesia. For all mice, body weight was measured daily during treatment before injection with isotope and/or weekly after the end of treatment (protocol 3). There were no side effects of treatment or deaths during any experiments. Findings are reported with reference to the particular protocol used to collect the tissues and data.
Tissue collection
Quadriceps, gastrocnemius, tibialis anterior (TA), and diaphragm were collected after euthanasia. Muscles were either cut in half across the mid-belly and prepared for cryosectioning or placed into preweighed, labeled Eppendorf tubes and snap frozen in liquid nitrogen for studies of RNA (left muscle), DNA or protein (right muscle), and nitrite concentration (TAs). Final muscle weight (protocol 1) was calculated.
Exercise-induced fiber damage
For the study of fiber damage induced by exercise (protocol 1), mice were injected with EBD at a dose of 1 mg/ml saline/10 g body wt., (54) at the beginning the 24 h of exercise. Diaphragm, quadriceps, gastrocnemius, and TA were isolated, bisected, snap frozen in molds and cut in cross-section (8 µm). Four pairs of sections, 150 µm apart were collected and coded. The fiber segments containing EBD were observed in four sections using a fluorescence microscope by scanning in lines, top to bottom directly across a section that was visualized through an optical grid. The proportion of EBD+/total fibers was determined by counting all fibers that intersected the right lower corner of a grid square. A minimum of five passes along the width of a section was made until at least 150 fibers were counted (>200 in diaphragm). Ratios of EBD+/total fibers sampled for each section were averaged for each animal and the mean (±SE) was calculated for each treatment group and compared using ANOVA and least significant difference statistics.
Gene expression
The expression of myf5 was determined (protocol 2) in tissue homogenates using Northern blots, prepared and probed as follows. Total RNA was prepared from quadriceps and diaphragm muscles of mdx, loaded into agarose gels (12 µg RNA), and blotted on nitrocellulose membranes according to standard protocols. Blots were probed with a digoxigenin-labeled riboprobe (1.4 kb) made against the antisense strand of myf5, as reported previously (33, 55, 56) . The blots were visualized by exposing against X-ray film after CSPD chemiluminescence detection. Bands in Northern blots were scanned using micro-densitometry software (MCID, St. Catherines, Ontario). Band intensity (minus background) was normalized to 18S RNA, which is invariant in expression, rather than against a contractile or housekeeping protein, which often varies in expression as muscles develop or are remodeled by dystrophy and regeneration. 18S RNA was identified by molecular weight in ethidium bromide gels.
In one experiment, myf5 expression was localized in muscle sections using in situ hybridization. The location of proliferating cells was identified using autoradiography for [ 3 H]thymidine incorporation into DNA. Muscles were collected at the end of exercise, and sections were collected onto glass slides processed for combined autoradiography and in situ hybridization for myf5 using the same riboprobe as above, visualized using an alkaline phosphatase-linked antidigoxigenin antibody as reported (33). Hybridization was specific in detecting much less than 0.5 ng of probe. Negative controls for in situ hybridization experiments included experiments processed by omitting riboprobe or the anti-digoxigenin antibody, after RNase treatment, and using a riboprobe made against the sense strand of myf5 sequence. Sections were viewed and photographed on an Olympus BH2-RFCA photomicroscope using Fuji color slide film (ASA 400). Muscle sections were observed for nuclei in myogenic cells (expressing myf5 by in situ hybridization) that contained three or more silver grains, marking DNA synthesis. Slides were scanned on an Olympus film scanner ES-10 and compiled into plates using Corel v.10 software.
DNA synthesis
DNA extracted from muscles (protocol 2) was used to measure [ 3 H]thymidine incorporation into new DNA using scintillation counting, as reported previously (43) . Muscle was minced on ice, placed in tubes, homogenized in PBS on ice and centrifuged (2000 g at 0°C, 10 min). The supernatant was transferred to a 15 ml tube containing 5 ml methanol, and DNA was allowed to precipitate overnight at −20°C. Samples were centrifuged (4000 g at 0°C, 30 min) to pellet DNA, the supernatant discarded, and the pellet redissolved in 0.5 ml 2% Triton containing 2% SDS. Samples were stored at 4°C to dissolve the pellet, pipetted into scintillation vials with 5 ml of Ready Safe™ scintillation fluid (Beckman; Fullerton, CA) and placed in a scintillation counter (LS 6500, Beckman-Coulter Inc.). Counts over 15 min were collected, and the sample count per minute (cpm) was standardized to muscle weight and expressed as the mean ± SE for each group.
Nitrite assay
Nitrite levels (protocol 2) were determined using standard protocols (57) (58) (59) (60) . TA muscles were ground at −70°C, suspended in 1.2 ml of buffer (50 mM TrisHCl, 1 mM EDTA, 1 mM dithiothreitol), and centrifuged at 12,000 g for 20 min. Supernatant was filtered (Nalgene syringe filter, 0.2 µm) and boiled (7 min) to precipitate dissolved protein. Samples were spun at 11,000 g for 5 min, and supernatants were collected and frozen at -70°C for assay.
Nitrite levels were measured using a colorimetric Greiss reaction as an indirect measure of NOS activity (57), calibrated against a standard curve of sodium nitrite (1-40 µM). Nitrates in a 200µl aliquot of supernatant were reduced to nitrites using nitrate reductase (10 µl of 5 U/ml, Sigma) (1 h in the presence of 10 µl of 6.0 mM nicotinamide adenine dinucleotide phosphate, and 10 µl of 200 µM flavin adenine dinucleotide, in the dark). Excess cofactor was removed by oxidation with 10 µl of 2 U/ml of lactic dehydrogenase and 5 µl of 1 M sodium pyruvate. Aliquots (150 µl) were placed in wells of an ELISA plate to which 75 µl of ice-cold 14 mM 4,4-diaminodiphenylsulfone (dapsone) in 2 M HCl and 75 µl of 4 mM N-1-napthylethylenediamine were added. After 5 min, absorbance at 550 nm was read (duplicate samples) with a plate reader. The concentration of nitrite was calculated, and values were standardized to muscle weight.
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Statistics
Comparisons of score data were made using ANOVA and post hoc least significant difference (LSD) statistics. Frequency distributions (EBD experiments) were tested for significance using Chi-squared statistics. Results are plotted as mean ± SE (n=8-10). A probability of P < 0.05 used to indicate a significant difference. Only significant changes are reported.
RESULTS
Animal and muscle weight
Data on animal and muscle weight from protocol 1 indicated that deflazacort treatment was accompanied by small gains in muscle weight normalized to body weight (P<0.05) for quadriceps ( Fig. 2) and gastrocnemius (not shown) compared with the placebo group. Diaphragm muscle weight relative to body weight did not change with treatment.
Voluntary exercise
A single 24 h event of running exercise was used to induce physiological fiber damage in mdx muscle. Animals in the placebo group ran 0.13 ± 0.03 km/g body wt., while other groups ran up to 0.3 km/g in 24 h. Total distance run by different animals ranged from 0.42 to 11.09 km.
Exercise-induced fiber damage -pilot study
The state of dystrophic muscle fibers was quantified as the proportion of total muscle fibers that were permeable to the fluorescent dye, EBD, during the exercise period. Immediately thereafter (data from protocol 1) sectioned muscles displayed large and small focal regions of EBD+ fibers (Fig. 3A) . In a pilot study of untreated mdx mice, 24 h of voluntary exercise increased fiber damage (EBD+ fibers/total fibers sampled) compared with nonexercised animals in quadriceps (P<0.01 by Chi-square statistics with Yates' correction; Fig. 3B ) and also in TA, diaphragm, and gastrocnemius (P<0.05; not shown). On this basis, quadriceps was selected for examination during treatment and exercise experiments under protocol 1.
In nonexercised animals in protocol 1, the D+LA treatment group showed a significantly lower proportion of EBD+ quadriceps fibers than all other groups (P<0.01), indicating that D+LA treatment was highly successful in reducing fiber damage measured by EBD permeation during mdx mouse muscular dystrophy (Fig. 3C) . Deflazacort attenuated the large increase in quadriceps fiber damage that was observed post-exercise in the placebo group. The exercised group treated with D+LA had a lower proportion of EBD+ quadriceps fibers compared with the exercised placebo group (P<0.01), although higher than in nonexercised animals after D+LA.
Regeneration from exercise-induced fiber damage
Myf5 expression was previously established as an indicator of myogenic regeneration, as reported (56) . It is observed in activated satellite cells, myoblasts, and myocytes soon after regeneration starts, and similar to other muscle regulatory genes, myf5 expression persists in newly-formed muscle fibers (myotubes) during maturation (55, 56, 61, 62) . Without exercise, myf5 is expressed in mdx muscles due to ongoing damage and regeneration associated with muscular dystrophy. In the current experiments (protocol 2), in nonexercised mice the level of Page 6 of 24 (page number not for citation purposes) myf5 expression in quadriceps was reduced by treatment with deflazacort and was further reduced by the combined D+LA and D+LN treatments (Fig. 4) .
Myf5 expression was twofold higher in quadriceps muscles as a result of 24 h of voluntary exercise, consistent with the character of contraction-induced fiber damage in X-linked muscular dystrophy. In protocol 2, muscle was collected at 4 days after exercise-induced damage, a time typically demonstrating active regeneration (61, 63, 64) . By comparison, the exercise-related increase in myf5 expression by quadriceps muscle (and gastrocnemius, not shown) was much lower in animals treated with deflazacort and was nearly eliminated after treatment with D+LA.
Effects of treatment on total nitrite levels
Total nitrite concentration in TA muscle was used as a gross measure of total NO production. Since inflammatory cells including macrophages release NO in inflamed tissues, it was expected that the anti-inflammatory effects of deflazacort would reduce nitrite levels in dystrophic muscle. Nitrite levels were decreased by 50-70% of the placebo level, in all groups treated with deflazacort, independent of exercise (ANOVA, LSD, P<0.05) as shown in Fig. 5 .
DNA synthesis
Cell proliferation in mdx quadriceps muscle at the end of protocol 2 (4 days after exercise or not) was measured using scintillation counts of muscle DNA. Representative sections of quadriceps muscle sampled from two animals in each group were processed for autoradiography and in situ hybridization for myf5 RNA expression, as reported previously (56) to identify the nature of proliferating cells. Cells in S-phase during and after isotope injection were identified by nuclei overlain with deposited silver grains and were localized largely (~75%) within myogenic, mononuclear cells (i.e., positive for myf5 RNA) (Fig. 6A) , in addition to labeling in endothelial cells, leucocytes, and fibroblasts. Approximately one-half of the myf5-expressing mononuclear cells displayed nuclei labeled with silver grains. In sections from the D+LA treatment group, there were very few foci of necrotic fibers, fibers undergoing phagocytosis, or new myotubes compared with those typical of placebo-treated mice.
In mice that were not exercised, DNA synthesis in quadriceps muscle was increased threefold in the group treated with D+LA compared with the placebo or deflazacort groups (Fig. 6B) . By contrast, 4 days after the 24 h period of voluntary exercise muscle cell DNA synthesis was not different between groups, as indicated by isotope incorporation. Identical findings were demonstrated by gastrocnemius and diaphragm muscles (data not shown).
Long-term effects on function in mdx mouse muscular dystrophy
The persistence of treatment effects on overall muscle function (distance run compared among treatment groups in protocol 1 and protocol 3) was measured in mdx mice treated with placebo, deflazacort, or D+LA as before. In one arm this experiment, half of each group was allowed to exercise after 17 days treatment (identical to those in protocol 1; referred to as "short-term" animals). In the other arm of the study, the other half of each group was maintained for 3 additional months before the 24 h period of exercise (protocol 3, "long-term animals"). Total distance run (normalized to body weight to account for changes in weight with age and the effects of differential wheel loading on distance running capacity, ref 53 ) was used as a gross index of muscle function and animal health.
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Comparing distance run by long-term animals, distance (normalized to body weight) was significantly increased as a result of earlier treatment with deflazacort (Fig. 7) . Three months after treatment, long-term animals treated with deflazacort ran ~2.5-fold further than placebo (deflazacort, 0.184±0.02 km/g body weight; placebo, 0.07±0.010 km/g) (ANOVA P<0.01). The group treated with D+LA ran further (0.2 ±0.2 km/g) than those treated only with deflazacort.
The distance run by mdx mice 3 months after the end of treatment was also different from that run by the short-term animals, immediately after treatment for 3 wk. Total distance run decreased over time in the placebo group (P<0.05) due to progression of mdx mouse muscular dystrophy. Deflazacort treatment abrogated the typical decline in the distance run, as noted by similar performance between steroid-treated animals in the short-term and long-term groups. Notably, mice treated with D+LA ran significantly further in the longer term, 3 months after the end of treatment, than the comparable short-term group, immediately after treatment (P<0.01).
DISCUSSION
These experiments demonstrate the effects of a treatment with deflazacort and L-arginine that not only spared dystrophic muscle from exercise-induced damage (and the ensuing regeneration from that muscle injury) and decreased the "background" severity of dystrophy in nonexercised mdx mice but additionally resulted in long-term potentiation of a persistent gain in function accorded by deflazacort alone. It is important to distinguish between these effects to reduce a hallmark feature of injury to dystrophic muscle from previous reports of the same treatment on regeneration from traumatic injury. The combined treatment with deflazacort and L-arginine was previously shown to promote muscle repair after a crush injury and also reduce central nucleation, a histological marker of the fiber regeneration caused by the progression of mouse muscular dystrophy. The present findings extend that effect of D+LA treatment to include significant protection from the fiber injury that is associated with a physiological level of activity, namely voluntary-running exercise for a period of 24 h. Use of EBD penetration into fibers with permeable membranes demonstrated in untreated mdx mice that exercise increased the proportion of fibers with permeable membranes. This was anticipated for muscle susceptible to contraction-induced degeneration. Studies of myf5 gene expression, a recognized marker of regeneration that persists until the newly-formed muscle has matured, showed that all treatments with deflazacort reduced the background activity of ongoing dystrophy. When combined with Larginine, deflazacort also stimulated muscle precursor cell proliferation in the nonexercised mdx mice. In the same muscles, the concentration of utrophin protein expressed in dystrophic muscle had approximately doubled after deflazacort plus L-arginine treatment (17) . Taken together, the findings suggest that damage to dystrophic muscle by exercise may largely be reduced, with consequently less need for regeneration after treatment with deflazacort plus L-arginine. This may account for the persistent functional gain that accompanied the combined treatment.
The mechanism that could account for such prevention of degeneration is likely more complex than reducing membrane susceptibility to exercise-related injury. Muscles from mdx mice treated with D+LA showed an exercise-dependent increase in permeability to EBD without a concomitant increase in myogenic damage (and subsequent repair), suggesting that permeability to EBD does not strictly correlate to fiber damage that will require new myogenesis. Although the experiments on total nitrite levels were not informative regarding changes in NO levels with different treatments, the results encourage the notion that increasing NO may be useful for augmenting the benefits of treatment with deflazacort, possibly by utrophin-related stabilization
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of stretch-related calcium-leak channel opening (65) . Further experiments using sensitive tools such as NO entrapment and electrospin resonance spectroscopy would address whether treatment did raise NO concentrations in muscle. The potentiation of a deflazacort-related functional gain that resulted from addition of L-arginine to treatment suggests that the slow turnover of utrophin (16) , which has a somewhat weaker anchorage to the DGC than dystrophin (66) , and ongoing increases in nNOS expression (33) may cumulatively alleviate the progression of dystrophy for some time after the end of treatment while the DGC is stabilized. Figure 8 presents a schematic of the pathophysiology of dystrophin-deficient myopathy, which identifies stages where the combined treatment with deflazacort and L-arginine appears to have a beneficial effect to alleviate the decline in function. It will be important for future studies to establish the persistence of this potentiation in functional gain and how it relates to the longer term outcome of mdx mouse muscular dystrophy.
Sarcolemmal disruptions were visualized using EBD, which binds to albumin in the circulation and diffuses into fibers that display sarcolemmal discontinuities. Deflazacort and D+LA treatments both reduced the proportion of EBD+ fibers in muscles of nonexercised animals, consistent with the earlier findings of reduced severity of mdx mouse dystrophy (33). EBD infiltration was unexpectedly increased after exercise in the mice treated with D+LA. This observation suggests that membrane leakiness was increased as a result of exercise, even under conditions where inflammation and total nitrite levels were each reduced relative to placebo. Two lines of evidence from the same groups of animals may account for this result. First, treatment with D+LA increased the concentrations of utrophin and CAPON, the NOS-I anchor protein, over placebo levels (17) . Second, a parallel experiment showed that in the same D+LA group, myf5 expression was not increased by prior exposure to voluntary exercise, 4 days earlier (under protocol 2, see Fig. 4 ). Together these observations are interpreted as suggesting that D+LA treatment increased membrane resilience to the extent that exercised muscle displayed fiber permeability to EBD without severe disruption that would be sufficient to induce significant muscle regeneration and myf5 expression.
Consistent with that notion, the stability of a modified cytoskeleton (17) would be slow to evolve, since utrophin synthesis is slow, and the rate of utrophin incorporation into the DGC may also be slow (16) . As well, there is evidence that entry to another albumin-linked marker, similar to EBD (Dr. R. Crameri, personal communication) or ethidium bromide (67) can rise transiently without correlating to the level of regeneration that ensues from fiber damage and the consequent secondary proliferation of myogenic precursor cells. Further consistent with this interpretation is the observation that cell proliferation (DNA synthesis) was increased in the absence of exercise in the D+LA group and that 4 days after exercise in that treatment group, had returned to placebo levels. The latter finding agrees with a previous report that proliferation rises for a short period after exercise and returns to pre-exercise levels after 4 days (68). As well, L-arginine treatment alone has stimulated brief increases in muscle cell proliferation (44) . These observations suggest a "normalization" of the hyperactivation state of satellite cells by D+LA treatment and voluntary exercise in the dystrophic mouse (37, 43, 44, 69, 70) . This laboratory has preliminary evidence that satellite cell activation on mdx fibers in culture is fivefold or more times the level of activation on normal muscle fibers (Wozniak and Anderson, unpublished data). The high level of activation apparently results from loss of NO signaling in dystrophic muscle, due to a downregulation of nNOS from the cytoskeleton that seems to release satellite cells from the typical quiescent state that is observed in normal adult muscle. Overall, the working hypothesis proposes that the balance between quiescence and activation is regulated by NO (37), such that either a
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decrease or an increase in NO will activate satellite cells (reviewed in refs 43, 44) . Although it is not established whether a shorter treatment interval with L-arginine would have a similar effect, the opportunity to improve the efficacy of deflazacort treatment is of particular interest, since treatment with deflazacort, supplemented with L-arginine, was protective against a physiologic level of fiber damage.
There was no increase in DNA synthesis in satellite cells observed in the muscles that displayed significant myf5 up-regulation in placebo-treated animals after exercise. This unexpected finding may relate to the schedule of tissue collection in protocol 2. Animals received exercise for 24 h. Data in protocol 2 formed the basis of Figs. 4-6 and were derived from muscles collected 4 days after the exercise-induced injury. At that time, the peak of muscle cell proliferation after injury would have passed (64, 71, 72) . By comparison, the expression of myf5, indicating the level of repair after the injury that was induced by exercise 4 days earlier, would be maintained for a longer interval until myotubes and regenerated segments had matured (55) .
Together, these experiments present evidence that combined treatment of mdx mice with deflazacort and L-arginine largely spared dystrophic muscle fibers from an exercise-related injury. This sparing effect was not directly related to cell proliferation or to the regeneration that was induced by exercise per se. It was more likely explained by many background effects on sarcolemmal stability, cytoskeletal make-up, reduced inflammation and dystrophy, and potentially the activation state of muscle satellite cells. Importantly, the long-term positive impact of this treatment in sustaining muscle function was substantial, since mdx mice did not show the typical progressive decline in voluntary running capacity that is expected with increasing age. Deflazacort plus L-arginine treatment for 3 wk starting shortly after the onset of dystrophy, apparently improved running capacity by ~50% compared with that immediately after treatment. Given that additional NOS expression and activity also benefit cardiac muscle structure and function in the mdx dystrophic mouse (51, 52) , such potentiation of a functional gain has important implications for treating DMD. and quadriceps muscle (right column) from placebo-treated mdx mice after exercise (Ex, top row) or not (No Ex, bottom row). Micrographs show fiber profiles that are fluorescent for EBD+ (white arrows), indicating membrane permeability during exposure to EBD. Original magnification ×150. B) Histogram of data from pilot experiment, conducted to investigate variations in exercise-induced fiber injury (assessed by the proportion of EBD+/total fibers) among different muscles (TA, tibialis anterior; Quad, quadriceps; Gastroc, gastrocnemius; and Dia, diaphragm) from untreated mdx mice, with (black bars) or without exercise (white bars). Although all muscles showed an exercise-induced increase in the proportion of EBD+ fibers (Chi-squared statistics, therefore, no SE is reported), quadriceps showed the largest increase and was selected as muscle for further studies. (*Significant difference from nonexercised group) C) Data from quadriceps muscles in a representative experiment under protocol 1 with (black bars) or without exercise (white bars). There was a significant increase in EBD+ fibers (proportionate to total fibers) in placebo-treated mice (Chi-squared statistics) after exercise. Proportionate fiber permeability (EBD+/total fibers) in groups without exercise was significantly lower in D+LA group. Proportion of EBD+ fibers showed no change with exercise in two groups (D and D+LN). Group treated with D+LA also displayed a significant increase in exercise-induced fiber permeability, as indicated by EBD infiltration. *Significant difference from nonexercised group after same treatment. #Significant difference from nonexercised placebo-treated group. 8 . Pathophysiology of muscular dystrophy and treatment effects. Key elements in pathophysiology of dystrophindeficient myopathy, exhibited in mdx mice and human Duchenne muscular dystrophy (DMD). A cascade of events develops from the primary loss of dystrophin, through interactions with the DGC (e.g., with nNOS down-regulation and satellite cell hyper-activation) and inflammation and fibrosis that occur in response to ongoing fiber damage. Events lead to progressive decline in function. Curved arrows indicate processes affected by treatment with D+LA that reduce or partly reverse the pathophysiology. Note one arrow, at "Utrophin and CAPON up-regulation," is indicated as positive (+), meaning the treatment increases (rather than reverses) this effect of the primary mutation.
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